(STAA) STAAR Surgical - Overview
Stock: Implantable Lens, Collamer Lens, Lens Delivery System
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 59.6% |
| Relative Tail Risk | -11.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.09 |
| Alpha | -36.69 |
| Character TTM | |
|---|---|
| Beta | 0.606 |
| Beta Downside | 0.325 |
| Drawdowns 3y | |
|---|---|
| Max DD | 79.28% |
| CAGR/Max DD | -0.46 |
Description: STAA STAAR Surgical January 16, 2026
STAAR Surgical (NASDAQ:STAA) designs, manufactures, and markets implantable Collamer lenses (ICLs) and associated delivery systems, as well as laser-based refractive procedures such as LASIK, to correct myopia, hyperopia, astigmatism, and presbyopia. Its customers are primarily ophthalmologists and eye-care facilities, and the firm reaches them through a direct sales force in the U.S., Japan, Germany, Spain, Canada, the U.K., and Singapore, complemented by distributors in China, Korea, India, and other European markets.
Key recent metrics: for Q2 2024 the company reported revenue of roughly $210 million, a 12 % year-over-year increase driven largely by a surge in ICL sales, which now account for about 80 % of total revenue; the ICL order backlog stood at approximately $300 million, indicating strong forward demand. The primary macro drivers are the rising global prevalence of myopia-particularly among younger populations in East Asia-and an aging demographic that fuels demand for presbyopia-correcting solutions. Within the broader health-care supplies sector, refractive-surgery volumes are expanding at an estimated 6 % compound annual growth rate, outpacing the relatively flat cataract-surgery market.
For a deeper dive into STAA’s valuation dynamics and how its growth profile compares to peers, you might find ValueRay’s analytical tools useful.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -96.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.09 > 0.02 and ΔFCF/TA -16.84 > 1.0 |
| NWC/Revenue: 112.6% < 20% (prev 96.93%; Δ 15.63% < -1%) |
| CFO/TA -0.07 > 3% & CFO -29.7m > Net Income -96.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.21 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.5m) vs 12m ago -0.42% < -2% |
| Gross Margin: 73.87% > 18% (prev 0.79%; Δ 7308 % > 0.5%) |
| Asset Turnover: 46.40% > 50% (prev 63.47%; Δ -17.07% > 0%) |
| Interest Coverage Ratio: -2.17 > 6 (EBITDA TTM -54.2m / Interest Expense TTM 29.0m) |
Altman Z'' 0.56
| A: 0.57 (Total Current Assets 321.2m - Total Current Liabilities 61.6m) / Total Assets 456.4m |
| B: -0.28 (Retained Earnings -129.7m / Total Assets 456.4m) |
| C: -0.13 (EBIT TTM -62.9m / Avg Total Assets 497.0m) |
| D: -1.32 (Book Value of Equity -135.7m / Total Liabilities 102.6m) |
| Altman-Z'' Score: 0.56 = B |
Beneish M -3.01
| DSRI: 0.87 (Receivables 63.6m/108.0m, Revenue 230.6m/341.2m) |
| GMI: 1.07 (GM 73.87% / 78.73%) |
| AQI: 1.76 (AQ_t 0.07 / AQ_t-1 0.04) |
| SGI: 0.68 (Revenue 230.6m / 341.2m) |
| TATA: -0.15 (NI -96.4m - CFO -29.7m) / TA 456.4m) |
| Beneish M-Score: -3.01 (Cap -4..+1) = AA |
What is the price of STAA shares?
Over the past week, the price has changed by -2.55%, over one month by -21.87%, over three months by -35.86% and over the past year by -22.25%.
Is STAA a buy, sell or hold?
- StrongBuy: 3
- Buy: 0
- Hold: 10
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the STAA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 23.4 | 32.9% |
| Analysts Target Price | 23.4 | 32.9% |
| ValueRay Target Price | 12.2 | -30.4% |
STAA Fundamental Data Overview February 03, 2026
P/S = 4.0569
P/B = 2.6443
P/EG = -4.89
Revenue TTM = 230.6m USD
EBIT TTM = -62.9m USD
EBITDA TTM = -54.2m USD
Long Term Debt = 39.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.31m USD (from shortTermDebt, last quarter)
Debt = 39.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -137.0m USD (from netDebt column, last quarter)
Enterprise Value = 781.9m USD (935.5m + Debt 39.1m - CCE 192.7m)
Interest Coverage Ratio = -2.17 (Ebit TTM -62.9m / Interest Expense TTM 29.0m)
EV/FCF = -19.77x (Enterprise Value 781.9m / FCF TTM -39.5m)
FCF Yield = -5.06% (FCF TTM -39.5m / Enterprise Value 781.9m)
FCF Margin = -17.15% (FCF TTM -39.5m / Revenue TTM 230.6m)
Net Margin = -41.79% (Net Income TTM -96.4m / Revenue TTM 230.6m)
Gross Margin = 73.87% ((Revenue TTM 230.6m - Cost of Revenue TTM 60.3m) / Revenue TTM)
Gross Margin QoQ = 82.21% (prev 74.00%)
Tobins Q-Ratio = 1.71 (Enterprise Value 781.9m / Total Assets 456.4m)
Interest Expense / Debt = 4.66% (Interest Expense 1.82m / Debt 39.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -49.7m (EBIT -62.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.21 (Total Current Assets 321.2m / Total Current Liabilities 61.6m)
Debt / Equity = 0.11 (Debt 39.1m / totalStockholderEquity, last quarter 353.8m)
Debt / EBITDA = 2.53 (negative EBITDA) (Net Debt -137.0m / EBITDA -54.2m)
Debt / FCF = 3.47 (negative FCF - burning cash) (Net Debt -137.0m / FCF TTM -39.5m)
Total Stockholder Equity = 359.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -19.39% (Net Income -96.4m / Total Assets 456.4m)
RoE = -26.81% (Net Income TTM -96.4m / Total Stockholder Equity 359.4m)
RoCE = -15.79% (EBIT -62.9m / Capital Employed (Equity 359.4m + L.T.Debt 39.1m))
RoIC = -13.83% (negative operating profit) (NOPAT -49.7m / Invested Capital 359.4m)
WACC = 7.97% (E(935.5m)/V(974.6m) * Re(8.15%) + D(39.1m)/V(974.6m) * Rd(4.66%) * (1-Tc(0.21)))
Discount Rate = 8.15% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.28%
Fair Price DCF = unknown (Cash Flow -39.5m)
EPS Correlation: -53.66 | EPS CAGR: -6.47% | SUE: -0.48 | # QB: 0
Revenue Correlation: -16.50 | Revenue CAGR: 13.46% | SUE: 0.49 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.03 | Chg30d=+0.000 | Revisions Net=+2 | Analysts=5
EPS next Year (2026-12-31): EPS=0.37 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+2663.2% | Growth Revenue=+21.4%